RP-HPLC is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-02-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Using a linear regression analysis on a plot of corrected percent divergence (amino acid changes per 100 amino acids) as a function of date of divergence from humans for different MIPOL1 orthologs (see Fig.5), it is estimated that a 1% change in amino acids in the MIPOL1 protein takes 5.68 million years. MIPOL1 protein is evolving at a moderate rate relative to fast evolving protein such as fibrinogen alpha, and slow evolving proteins such as cytochrome C.
At 3%, calcium is the fifth most abundant element in the Earth's crust, and the third most abundant metal behind aluminium and iron. It is also the fourth most abundant element in the lunar highlands. Sedimentary calcium carbonate deposits pervade the Earth's surface as fossilised remains of past marine life; they occur in two forms, the rhombohedral calcite (more common) and the orthorhombic aragonite (forming in more temperate seas). Minerals of the first type include limestone, dolomite, marble, chalk, and Iceland spar; aragonite beds make up the Bahamas, the Florida Keys, and the Red Sea basins. Corals, sea shells, and pearls are mostly made up of calcium carbonate. Among the other important minerals of calcium are gypsum (CaSO4·2H2O), anhydrite (CaSO4), fluorite (CaF2), and apatite ([Ca5(PO4)3X], X = OH, Cl, or F) The major producers of calcium are China (about 10000 to 12000 tonnes per year), Russia (about 6000 to 8000 tonnes per year), and the United States (about 2000 to 4000 tonnes per year). Canada and France are among the minor producers. In 2005, about 24000 tonnes of calcium were produced; about half of the world's extracted calcium is used by the United States, with about 80% of the output used each year. In Russia and China, Davy's method of electrolysis is still used, but is instead applied to molten calcium chloride. Since calcium is less reactive than strontium or barium, the oxide–nitride coating that results in air is stable and lathe machining and other standard metallurgical techniques are suitable for calcium. In the U.S.
=== Efficacy === In type II diabetic patients, acarbose averages an absolute decrease of 0.8 percentage points in HbA1c, which is a decrease of about 10% in typical HbA1c values in diabetes studies. Individuals with higher baseline levels show higher reductions, about an 0.12% additional decrease for each point of baseline HbA1c. Its effect on postprandial glucose, but not on HbA1c, scales with dose. Among diabetic patients, acarbose may help reduce the damage done to blood vessels and kidneys by reducing glucose levels. A Cochrane systematic review assessed the effect of alpha-glucosidase inhibitors in people with prediabetes, defined as impaired glucose tolerance, impaired fasting blood glucose, elevated glycated hemoglobin A1c (HbA1c). It was found that acarbose reduced the incidence of diabetes mellitus type 2 when compared to placebo, however there was no conclusive evidence that acarbose, when compared to diet and exercise, metformin, placebo, or no intervention, improved all-cause mortality, reduced or increased risk of cardiovascular mortality, serious or non-serious adverse events, non-fatal stroke, congestive heart failure, or non-fatal myocardial infarction. Several studies showed that glucosidase inhibitors and alpha-amylase inhibitors promote loss of visceral fat and waist by acting as calorie restriction mimetics (linked to their acarbose-like action).
baiCD (NAD+-dependent-3-oxo-𝚫4-cholenoic acid oxidoreductase): Located directly downstream of baiB on the bai operon, baiCD functions to catalyze C4-C5 oxidation, creating a 3-dehydro-Δ4-cholic-acid-CoA intermediate. This enzyme performs a reduction that introduces a new double bond between C4-C5 in one of the bile acid’s aromatic rings. Along with baiA2, baiCD acts twice in the 7ɑ-dehydroxylation pathway, catalyzing the first and last two redox reactions. baiE (7-ɑ dehydratase): Located directly downstream of baiCD, the baiE gene codes for a 7-ɑ dehydratase enzyme that performs a diaxial trans elimination of water from the baiCD-produced bile acid intermediate. The mechanism for this transformation is not known, but previous research indicates that it is similar to that of the also elusive baiI, which may encode for 7-β dehydratase. baiE and baiI are believed to likely have similar mechanisms due to their homologous amino acid sequences and apparent stereospecificity as well. baiF (bile-acid CoA hydrolase): Immediately downstream of baiA2, baiF codes for a bile-acid CoA hydrolase that removes the CoA group from bile acid intermediates. One research study revealed that this removed CoA is transferred and conjugated to cholic acid. The baiF gene product resembles carnitine dehydratase in Escherichia coli, which is classified as a thioesterase. However, baiF does not resemble any known thioesterases, so some researchers propose that baiF encodes a novel family of thioesterases.
==== Ranges ==== Each Range comprises two or more districts or one district divided into multiple police districts. The Range is headed by a Deputy Inspector General of Police (DIG). In West Bengal there are 10 ranges. Besides, there are DIG ranked officers in the department of Traffic, Railways, States Crime Records Bureau (SCRB), CID West Bengal, Anti Corruption Bureau (ACB), AP Barrackpore, AP Eastern Frontier Rifles (EFR) Salua, AP North Bengal, AP Durgapur, AP Siliguri, Border, Enforcement Bureau (EB), Intelligence Bureau, Fire Services, Headquarter (HQ), Police Training Center (PTS), Training, Personnel & Weapon, Provisioning, Telecommunication, WBNVF, Civil Defence etc.
Sources: en.wikipedia.org
Downstream processing refers to purification of chemicals, pharmaceuticals and food ingredients produced by fermentation or synthesized by plant and animal tissues, for example antibiotics, citric acid, vitamin E, and insulin. Fractionation refers to a purification strategy in which some relatively inefficient purification method is repeatedly applied to isolate the desired substance in progressively greater purity. Electrolysis refers to the breakdown of substances using an electric current. This removes impurities in a substance that an electric current is run through Sublimation is the process of changing of any substance (usually on heating) from a solid to a gas (or from gas to a solid) without passing through liquid phase. In terms of purification - material is heated, often under vacuum, and the vapors of the material are then condensed back to a solid on a cooler surface. The process thus in its essence is similar to distillation, however the material which is condensed on the cooler surface then has to be removed mechanically, thus requiring different laboratory equipment. Bioleaching is the extraction of metals from their ores through the use of living organisms. Separation process From Crystallization
Like surface tension, adsorption is a consequence of surface energy. In a bulk material, all the bonding requirements (be they ionic, covalent, or metallic) of the constituent atoms of the material are fulfilled by other atoms in the material. However, atoms on the surface of the adsorbent are not wholly surrounded by other adsorbent atoms and therefore can attract adsorbates. The exact nature of the bonding depends on the details of the species involved, but the adsorption process is generally classified as physisorption (characteristic of weak van der Waals forces) or chemisorption (characteristic of covalent bonding). It may also occur due to electrostatic attraction. The nature of the adsorption can affect the structure of the adsorbed species. For example, polymer physisorption from solution can result in squashed structures on a surface. Adsorption is present in many natural, physical, biological, and chemical systems and is widely used in industrial applications such as heterogeneous catalysts, activated charcoal, capturing and using waste heat to provide cold water for air conditioning and other process requirements (adsorption chillers), synthetic resins, increasing storage capacity of carbide-derived carbons and water purification. Adsorption, ion exchange, and chromatography are sorption processes in which certain adsorbates are selectively transferred from the fluid phase to the surface of insoluble, rigid particles suspended in a vessel or packed in a column.
=== Tennessee === On March 21, 2024, the State of Tennessee enacted legislation called the ELVIS Act, aimed specifically at audio deepfakes, and voice cloning. This legislation was the first enacted legislation in the nation aimed at regulating AI simulation of image, voice and likeness. The bill passed unanimously in the Tennessee House of Representatives and Senate. This legislation's success was hoped by its supporters to inspire similar actions in other states, contributing to a unified approach to copyright and privacy in the digital age, and to reinforce the importance of safeguarding artists' rights against unauthorized use of their voices and likenesses.
==== Stable isotope labels ==== An approach for relative quantification that is more costly and time-consuming, though less sensitive to experimental bias than label-free quantification, entails labeling the samples with stable isotope labels that allow the mass spectrometer to distinguish between identical proteins in separate samples. One type of label, isotopic tags, consist of stable isotopes incorporated into protein crosslinkers that causes a known mass shift of the labeled protein or peptide in the mass spectrum. Differentially labeled samples are combined and analyzed together, and the differences in the peak intensities of the isotope pairs accurately reflect difference in the abundance of the corresponding proteins. Absolute proteomic quantification using isotopic peptides entails spiking known concentrations of synthetic, heavy isotopologues of target peptides into an experimental sample and then performing LC-MS/MS. As with relative quantification using isotopic labels, peptides of equal chemistry co-elute and are analyzed by MS simultaneously. Unlike relative quantification, though, the abundance of the target peptide in the experimental sample is compared to that of the heavy peptide and back-calculated to the initial concentration of the standard using a pre-determined standard curve to yield the absolute quantification of the target peptide.
The rates of azoospermia increased with greater CPA dosage, which was attributed to the additional AR antagonism of higher doses of CPA. Significant spermatogenesis still occurs with 50 mg/day CPA alone, but spermatogenesis is significantly reduced compared to normal. At a dosage of 200 mg/day, CPA has been found to produce azoospermia (sperm count of less than 1 million/mL) in men within 8 to 10 weeks of treatment. However, fertility is generally lost even at a lower dosage of CPA of 100 mg/day because there is complete inhibition of the accessory sex glands and hence an absence of semen production and ejaculate upon orgasm. Ejaculate volume decreases at a dosage of 50 mg/day and decreases to almost zero after 6 weeks of high-dose CPA therapy. The effects of CPA on fertility are completely reversible. This has been demonstrated in clinical studies of male adolescents and adults treated with CPA continuously for 6 to 7 years.
Sources: en.wikipedia.org
=== Books === Wadden, Thomas A.; Van Itallie, Theodore B. (1992). Treatment of the Seriously Obese Patient. Guilford Press. Stunkard, Albert J.; Wadden, Thomas A. (1993). Obesity: Theory and Therapy (2nd ed.). Raven Press. Brownell, Kelly D.; Wadden, Thomas A. (1998). The LEARN Program for Weight Control: Special Medication Edition. American Health Publishing. Wadden, Thomas A.; Stunkard, Albert J. (2002). Handbook of Obesity Treatment. Guilford Press. Wadden, Thomas A.; Bray, George A. (2018). Handbook of Obesity Treatment (2nd ed.). Guilford Press.
== Principle of chiral column chromatography == The chiral stationary phase, CSP, can interact differently with two enantiomers, by a process known as chiral recognition. Chiral recognition depends on various interactions such as hydrogen bonding, π-π interaction, dipole stacking, inclusion complexation, steric, hydrophobic and electrostatic interaction, charge-transfer interactions, ionic interactions etc, between the analyte and the CSP, to form in-situ transient-diastereomeric complexes. Most of the types of stationary phases can be classified as Pirkle type (Brush type), Protein-based, Cyclodextrins based, Polymer-based carbohydrates (polysaccharide-based CSPs), Macrocyclic antibiotic, Chiral crown ethers, imprinted polymers, etc.
To reduce radiation exposure, the American Society of Nuclear Cardiology (ASNC) issued dosage recommendations in 2010. The effective dose is 2.4 mSv for 13N-ammonia, 2.5 mSv for 15O-water, 7 mSv for 18F-fluorodeoxyglucose, and 13.5 mSv for 82Rb-rubidium chloride. Compliance with these recommendations is expected to reduce the average radiation exposure to = 9 mSv. The Ordinance on Radioactive Drugs or Drugs Treated with Ionizing Radiation § 2 AMRadV (in German) regulates the approval procedures for the marketability of radioactive drugs.
=== Receptors === Innate immune system senses intact peptidoglycan and peptidoglycan fragments using numerous PRRs (pattern recognition receptors) that are secreted, expressed intracellularly or expressed on the cell surface.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.